查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年亞太地區傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路
市場調查報告書
商品編碼
1562250

2030 年亞太地區傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路

Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 101 Pages | 訂單完成後即時交付

價格

2022年亞太傳染病治療市值為259.0461億美元，預計2030年將達到374.1507億美元；預計2022年至2030年複合年成長率為4.7%。

發展中國家不斷成長的機會推動亞太傳染病治療市場

傳染病發病率的不斷上升預計將增加發展中國家傳染病治療藥物的銷售。由於資料需求適度減少和嚴格的法規，亞太地區已成為一個適應性強且有利於商業的中心。此外，新興國家對健康研究和生命科學的高投入對於促進發展中國家的最新技術發揮關鍵作用，這反過來又支持了傳染病診斷和治療的傾向。例如，聯合國愛滋病規劃署呼籲到2025年投資290億美元，以滿足中低收入國家應對愛滋病的需求。因此，印度和韓國新興傳染病治療市場的重要傳染病治療產品製造商預計未來將見證利潤豐厚的機會。這是由於肝炎、HAI、HIV 和流感等傳染病的高流行所致；大量患者；人口可支配所得增加；改善醫療保健基礎設施；這些國家不斷成長的醫療旅遊業。

亞太地區傳染病治療市場概況

亞太傳染病治療市場細分為中國、印度、日本、韓國、澳洲和亞太其他地區。預計亞太地區在預測期內複合年成長率最快。由於全球醫療保健支出增加、慢性病和傳染病發病率增加以及老年人口基數不斷增加，預計該地區的市場將成長。中國常見流感、B型肝炎、感染性腹瀉等傳染病，印度常見傷寒、瘧疾、黃疸、結核病、愛滋病等。流感、B型肝炎、感染性腹瀉是我國常見的三大傳染病。根據Frontiers Public Health報道，2021年冬季流感高峰期恰逢該國爆發COVID-19。高。考慮到該國傳染病發病率不斷上升，世界銀行執行董事會批准為新興傳染病預防、準備和應對計畫提供3億美元貸款。這將有助於降低人畜共患病和其他新出現的健康威脅的風險。因此，傳染病發病率的上升以及為控制這些疾病而採取的措施預計將在未來幾年推動中國傳染病治療市場的發展。

亞太地區傳染病治療市場收入及 2030 年預測（百萬美元）

亞太地區傳染病治療市場區隔

亞太傳染病治療市場按藥物類別、適應症、給藥途徑、配銷通路和國家分類。

依藥物類別，亞太傳染病治療市場分為抗病毒、抗菌、抗真菌等。 2022 年，抗病毒藥物領域佔據最大的市場佔有率。

從適應症來看，亞太傳染病治療市場分為愛滋病毒、肝炎、結核病、流感、HPV等。 2022 年，HIV 佔據最大的市場佔有率。

根據給藥途徑，亞太傳染病治療市場分為口服、腸胃外、外用等。 2022 年，口腔細分市場佔據最大的市場佔有率。

從配銷通路來看，亞太傳染病治療市場分為醫院藥局、零售藥局等。 2022年，醫院藥局佔最大的市場佔有率。

依國家/地區分類，亞太傳染病治療市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。 2022年，中國在亞太傳染病治療市場佔有率中佔據主導地位。

艾伯維公司(AbbVie Inc)、安斯泰來製藥公司(Astellas Pharma Inc)、拜耳公司(Bayer AG)、霍夫曼-拉羅氏有限公司(F. Hoffmann-La Roche Ltd)、吉利德科學公司(Gilead Sciences Inc)、葛蘭素史克公司(GSK Plc)、默克公司(Merck & Co Inc)、輝瑞公司(Pfizer Inc) 和鹽野義公司(Shionogi & Co Ltd) 是亞太地區傳染病領域的一些領先公司疾病治療市場。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：亞太地區傳染病治療市場 - 主要市場動態

  • 亞太傳染病治療市場 - 主要市場動態
  • 市場促進因素
    • 傳染病病率上升
    • 越來越關注傳染病治療的經費與研發
  • 市場限制
    • 抗感染藥物抗藥性的出現及相關副作用
  • 市場機會
    • 發展中國家不斷成長的機會
    • 抗生素抗藥性威脅不斷升級
  • 未來趨勢
    • 產品批准和發布數量不斷增加
  • 促進因素和限制的影響：

第 5 章：傳染病治療市場 - 亞太市場分析

  • 2022-2030 年亞太地區傳染病治療市場收入

第 6 章：亞太地區傳染病治療市場分析 - 按藥物類別

  • 概述
  • 抗病毒劑
  • 抗菌
  • 抗真菌
  • 其他

第 7 章：亞太地區傳染病治療市場分析 - 按適應症

  • 概述
  • 愛滋病
  • 肝炎
  • 結核
  • 流感
  • HPV病毒
  • 其他

第 8 章：亞太地區傳染病治療市場分析 - 按給藥途徑

  • 概述
  • 口服
  • 注射用
  • 專題
  • 其他

第 9 章：亞太地區傳染病治療市場分析 - 按配銷通路

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 10 章：亞太地區傳染病治療市場 - 國家分析

  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區

第 11 章：傳染病治療市場-產業格局

  • 概述
  • 傳染病治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 12 章：公司簡介

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第 13 章：附錄

Product Code: BMIRE00030366

The Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.

Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.

Asia Pacific Infectious Disease Therapeutics Market Overview

The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.

Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Infectious Disease Therapeutics Market Segmentation

The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Growing Opportunities in Developing Nations
    • 4.4.2 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 Asia Pacific Infectious Disease Therapeutics Market Overview
    • 10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.8.1 Overview
      • 10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.10.1 Overview
      • 10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.12.1 Overview
      • 10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 GSK Plc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AbbVie Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Merck & Co Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Astellas Pharma Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation
  • Table 2. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 3. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 4. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 5. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 6. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 7. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 8. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 9. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 10. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 11. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 12. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 13. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 14. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 15. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 16. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 17. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 18. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 19. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 20. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 21. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 22. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 23. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 24. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 25. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 26. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 27. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 28. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 29. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 30. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Asia Pacific Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market